Vishria Bird Financial Group LLC Purchases 80 Shares of Johnson & Johnson (NYSE:JNJ)

Vishria Bird Financial Group LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 3.0% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,736 shares of the company’s stock after acquiring an additional 80 shares during the period. Vishria Bird Financial Group LLC’s holdings in Johnson & Johnson were worth $381,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Fisher Asset Management LLC grew its holdings in Johnson & Johnson by 0.7% during the 4th quarter. Fisher Asset Management LLC now owns 11,337,653 shares of the company’s stock valued at $1,463,124,000 after buying an additional 78,572 shares in the last quarter. Clearbridge Investments LLC grew its holdings in Johnson & Johnson by 0.5% during the 1st quarter. Clearbridge Investments LLC now owns 9,628,443 shares of the company’s stock valued at $1,345,960,000 after buying an additional 48,582 shares in the last quarter. Nordea Investment Management AB grew its holdings in Johnson & Johnson by 14.2% during the 1st quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock valued at $1,217,494,000 after buying an additional 1,079,751 shares in the last quarter. Swedbank grew its holdings in Johnson & Johnson by 5.5% during the 4th quarter. Swedbank now owns 4,001,754 shares of the company’s stock valued at $509,303,000 after buying an additional 209,665 shares in the last quarter. Finally, Manning & Napier Group LLC grew its holdings in Johnson & Johnson by 15.2% during the 4th quarter. Manning & Napier Group LLC now owns 1,908,720 shares of the company’s stock valued at $246,318,000 after buying an additional 252,348 shares in the last quarter. Institutional investors and hedge funds own 66.82% of the company’s stock.

A number of research analysts have weighed in on the company. Barclays assumed coverage on Johnson & Johnson in a report on Friday, June 21st. They set a “hold” rating and a $140.00 target price for the company. Wells Fargo & Co reaffirmed an “outperform” rating and set a $157.00 target price (up previously from $152.00) on shares of Johnson & Johnson in a report on Monday, May 6th. Credit Suisse Group set a $156.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a report on Thursday, July 18th. Morgan Stanley boosted their price objective on Johnson & Johnson from $134.00 to $145.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 17th. Finally, Goldman Sachs Group began coverage on Johnson & Johnson in a report on Tuesday, May 28th. They set a “buy” rating for the company. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Johnson & Johnson has a consensus rating of “Buy” and an average target price of $148.56.

Shares of NYSE JNJ traded up $0.27 during midday trading on Tuesday, hitting $130.43. 62,757 shares of the company’s stock were exchanged, compared to its average volume of 7,791,626. Johnson & Johnson has a 12-month low of $121.00 and a 12-month high of $148.99. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $343.51 billion, a P/E ratio of 16.00, a price-to-earnings-growth ratio of 2.22 and a beta of 0.69. The firm has a fifty day moving average price of $136.13.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The company had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same quarter in the previous year, the firm earned $2.10 earnings per share. Johnson & Johnson’s revenue was down 1.3% on a year-over-year basis. On average, equities research analysts forecast that Johnson & Johnson will post 8.6 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 2.91%. The ex-dividend date of this dividend is Monday, August 26th. Johnson & Johnson’s payout ratio is 46.45%.

In other Johnson & Johnson news, Director Marillyn A. Hewson acquired 3,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The stock was bought at an average price of $139.68 per share, with a total value of $419,040.00. Following the completion of the acquisition, the director now owns 3,000 shares of the company’s stock, valued at $419,040. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.23% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What are catch-up contributions?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.